One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
It Ain’t Over Till It’s Over…but It’s Never Over — Emerging and Reemerging Infectious Diseases
Anthony S. Fauci, M.D.
doi : 10.1056/NEJMp2213814
Vol. 387 No. 22
Prescribing Opioids for Pain — The New CDC Clinical Practice Guideline
Deborah Dowell, M.D., M.P.H., Kathleen R. Ragan, M.S.P.H., Christopher M. Jones, Pharm.D., Dr.P.H., Grant T. Baldwin, Ph.D., M.P.H., and Roger Chou, M.D.
doi : 10.1056/NEJMp2211040
The White House Conference on Hunger, Nutrition, and Health — A New National Strategy
Dariush Mozaffarian, M.D., Dr.P.H.
doi : 10.1056/NEJMp2213027
Mask Wars
Debra Malina, Ph.D., J. Alexander Navarro, Ph.D., Christopher McKnight Nichols, Ph.D., Bruno J. Strasser, Ph.D., and Meng Zhang, Ph.D.
doi : 10.1056/NEJMp2214296
Renin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease
Sunil Bhandari, Ph.D., Samir Mehta, M.Sc., Arif Khwaja, Ph.D., John G.F. Cleland, M.D., Natalie Ives, M.Sc., Elizabeth Brettell, B.Sc., Marie Chadburn, Ph.D., and Paul Cockwell, Ph.D. for the STOP ACEi Trial Investigators*
doi : 10.1056/NEJMoa2210639
Renin–angiotensin system (RAS) inhibitors — including angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) — slow the progression of mild or moderate chronic kidney disease. However, the results of some studies have suggested that the discontinuation of RAS inhibitors in patients with advanced chronic kidney disease may increase the estimated glomerular filtration rate (eGFR) or slow its decline.
Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy
Elizabeth A. Suarez, Ph.D., M.P.H., Krista F. Huybrechts, Ph.D., Loreen Straub, M.D., Sonia Hernández-DÃaz, M.D., Dr.P.H., Hendrée E. Jones, Ph.D., Hilary S. Connery, M.D., Ph.D., Jonathan M. Davis, M.D., Kathryn J. Gray, M.D., Ph.D., Barry Lester, Ph.D., Mishka Terplan, M.D., M.P.H., Helen Mogun, M.S., and Brian T. Bateman, M.D.
doi : 10.1056/NEJMoa2203318
Opioid agonist therapy is strongly recommended for pregnant persons with opioid use disorder. Buprenorphine may be associated with more favorable neonatal and maternal outcomes than methadone, but existing data are limited.
Trial of Deferiprone in Parkinson’s Disease
David Devos, M.D., Ph.D., Julien Labreuche, Ph.D., Olivier Rascol, M.D., Ph.D., Jean-Christophe Corvol, M.D., Ph.D., Alain Duhamel, M.D., Ph.D., Pauline Guyon Delannoy, M.L.S., Werner Poewe, M.D., Ph.D., Yaroslau Compta, M.D., Ph.D., Nicola Pavese, M.D., Ph.D., Evžen Růži�ka, M.D., Ph.D., Petr Dušek, M.D., Ph.D., Bart Post, M.D., Ph.D.,
doi : 10.1056/NEJMoa2209254
Iron content is increased in the substantia nigra of persons with Parkinson’s disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson’s disease, but its effects on disease progression are unclear.
Trial of Training to Reduce Driver Inattention in Teens with ADHD
Jeffery N. Epstein, Ph.D., Annie A. Garner, Ph.D., Adam W. Kiefer, Ph.D., James Peugh, Ph.D., Leanne Tamm, Ph.D., Ryan P. MacPherson, M.S., John O. Simon, M.A., and Donald L. Fisher, Ph.D.
doi : 10.1056/NEJMoa2204783
Teens with attention deficit–hyperactivity disorder (ADHD) are at increased risk for motor vehicle collisions. A computerized skills-training program to reduce long glances away from the roadway, a contributor to collision risk, may ameliorate driving risks among teens with ADHD.
Infantile and Childhood Hydrocephalus
William E. Whitehead, M.D., and Howard L. Weiner, M.D.
doi : 10.1056/NEJMra2116504
Bismuth Subsalicylate Poisoning
Christopher W. Meaden, M.D., and Diane P. Calello, M.D.
doi : 10.1056/NEJMicm2027922
Hiding in Plain Sight
Jwan A. Naser, M.B., B.S., Delvise Fogwe, M.D., Matthew Ho, M.B., B.Ch., B.A.O., Ph.D., Cristina Corsini Campioli, M.D., and Aditya Shah, M.B., B.S.
doi : 10.1056/NEJMcps2205021
Discontinuation of RAS Inhibitors in Advanced CKD — Has Equipoise Occurred?
Julie R. Ingelfinger, M.D.
doi : 10.1056/NEJMe2214315
Neonatal Outcomes after Use of Buprenorphine during Pregnancy
Elizabeth E. Krans, M.D.
doi : 10.1056/NEJMe2212967
Lack of Benefit of Iron Chelation in Early Parkinson’s Disease
Douglas Galasko, M.B., B.Ch., and Tanya Simuni, M.D.
doi : 10.1056/NEJMe2213120
Audio Interview: Five Disease Outbreaks beyond Covid-19
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2215488
Prolonging Cellular Life after Hypoxic Death
Holger K. Eltzschig, M.D., Ph.D.
doi : 10.1056/NEJMcibr2210456
